Key facts

Invented name
  • Triumeq
  • Triumeq
Active Substance
  • dolutegravir
  • abacavir
  • lamivudine
Therapeutic area
Infectious diseases
Decision number
P/0038/2023
PIP number
EMEA-001219-PIP01-11-M06
Pharmaceutical form(s)
  • Film-coated tablet
  • Dispersible tablet
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries

ViiV Healthcare UK Limited

E-mail: eu.paediatric-plans@gsk.com
Tel: +1 4388998201

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0038/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M06)

How useful do you find this page?